Aralez Pharmaceuticals Inc. (ARLZ-NASDAQ)

OUTLOOK
Aralez Pharmaceuticals, Inc. (ARLZ) recently announced the U.S. commercial launch of Zontivity® with 75 sales representatives targeting 12,000 cardiologists, primary care physicians, and vascular surgeons. Early data following the launch is very encouraging, with weekly new prescription numbers exceeding the prior high set by Merck. We will continue to track these numbers to determine if this positive early trend continues.

On June 27, 2017, Aralez announced that the U.S. District Court upheld the validity of two patents covering VIMOVO® and that no generic versions of VIMOVO® may be launched until at least the expiration of one of those patents. The earliest patent expiry is February 2023, however other patents related to VIMOVO® may extend patent protection to 2031.

Based on our financial model that uses a EV/revenue multiple of 5.0x based on projected 2021 revenues, with a 15% discount rate, ARLZ is valued at $6/share. Additional upside to this valuation is possible from increased sales of YOSPRALA® and/or accretive deals.

SUMMARY DATA

| 52-Week High | $6.26 |
| 52-Week Low | $1.14 |
| One-Year Return (%) | -62.60 |
| Beta | 1.37 |
| Average Daily Volume (sh) | 658,547 |

Shares Outstanding (mil) 66
Market Capitalization ($mil) $89
Short Interest Ratio (days) 1
Institutional Ownership (%) 36
Insider Ownership (%) 7

Annual Cash Dividend $0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates
Sales (%) -3.2
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A
P/E using 2017 Estimate -1.9
P/E using 2018 Estimate -2.1

ZACKS ESTIMATES

Revenue (In millions of $)

<table>
<thead>
<tr>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>8.1 A</td>
<td>12.6 A</td>
<td>13.6 A</td>
<td>20.0 A</td>
</tr>
<tr>
<td>2017</td>
<td>26.0 A</td>
<td>21.6 E</td>
<td>19.8 E</td>
<td>19.9 E</td>
</tr>
<tr>
<td>2018</td>
<td>100.0 E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>107.0 E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Earnings per Share (EPS is operating earnings before non-recurring items)

<table>
<thead>
<tr>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>-$0.65 A</td>
<td>-$0.27 A</td>
<td>-$0.32 A</td>
<td>-$0.55 A</td>
</tr>
<tr>
<td>2017</td>
<td>-$0.42 A</td>
<td>-$0.43 E</td>
<td>-$0.46 E</td>
<td>-$0.46 E</td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Business Update

Promising Early Data Following Zontivity® Launch

On June 7, 2017, Aralez announced the national commercial launch of Zontivity® in the U.S. The company had previously commenced a phased launch of Zontivity® in late April 2017 with 15 sales representatives targeting high volume physicians who treat post-myocardial infarction and peripheral artery disease (PAD) patients. As the following figure shows, the phased launch was very successful with 98% growth in new prescriptions (NRx) after five weeks, compared to the five weeks preceding the phased launch.

![NRx Growth Targeted HCPs](chart.png)

The company’s full sales force (approximately 75 representatives) is now promoting Zontivity® to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons. The early numbers following the launch look quite promising. According to management, for the week ending June 23, 2017, NRx hit an all-time high of 145 (Merck’s previous high was 137), which was a 39% increase over the previous week and following multiple weeks of flat total prescriptions (TRx), that number increased 48% to 274.

The company is focused on continuing the momentum seen following the launch through the following strategic initiatives:

- Continuing to enhance managed care coverage, where Zontivity® is now covered by approximately 85% of Commercial Lives. The four largest pharmacy benefit managers (PBMs) are covering Zontivity®, with less than 15% of Commercial Lives requiring a prior authorization, which the company hopes to cut in half in the near term.

- Focusing on those patients with PAD and/or patients with a history of MI who also have diabetes and/or are smokers.

- Reducing patient co-pays to approximately $6/month through subsidy programs.

We are encouraged by the early data following the launch of Zontivity® and we will continue to monitor prescribing data closely over the next few quarters to determine whether this trend continues.
YOSPRALA® Numbers Improving Following Price Change

Following a lackluster launch, Aralez has initiated a number of changes regarding YOSPRALA®. The first change was a 32% reduction in the U.S. sales force, which was disclosed in April 2017. The other major change was a new pricing strategy for YOSPRALA®. The new pricing program is aimed at allowing all patients access to YOSPRALA® for only $10 per month, regardless of whether a patient has insurance or not or what the copay is if insured. This compares to a $20 target copay that was instituted at launch. The following graph shows a sizeable increase in prescriptions for YOSPRALA® following implementation of the price change. In addition, rejections have decreased from 60% to approximately 30%. We will continue to monitor these numbers closely to determine if this trend continues.

VIMOVO® Patents Upheld

On June 27, 2017, Aralez announced that the U.S. District Court for the District of New Jersey upheld the validity of two patents that cover VIMOVO®. A subsidiary of Aralez filed patent infringement lawsuits against Dr. Reddy's Laboratories Inc., Lupin Pharmaceuticals Inc., and Mylan Pharmaceuticals, Inc. in April 2011, July 2011, and June 2013, respectively, related to Abbreviated New Drug Applications (ANDAs) filed with the U.S. FDA for generic versions of VIMOVO®. The lawsuit alleged infringement of U.S. Patents 8,557,285 and 6,926,907, and the court’s decision will prevent any generic versions of VIMOVO in the U.S. until at least the expiry of the ‘907 patent (Feb. 2023), although VIMOVO® may have protection due to other patents until 2031. Perhaps most importantly, the prevention of generic competitors to VIMOVO® protects Aralez’s guaranteed minimum royalty from Horizon Pharma of $7.5 million per year based on the licensing agreement between the two firms. Lastly, this could lend support to the company in their patent fight with Teva Pharmaceuticals, which is attempting to bring a generic version of YOSPRALA® to market. The ‘907 patent is one of the patents being challenged by Teva, however that case is likely years away from a verdict.

Conclusion and Valuation

Following a very rough first half of 2017 for Aralez, it appears as though the company has at least stabilized, and may be in the process of heading in the right direction. The early numbers for Zontivity® look promising, and the company’s focus on high-risk PAD patients may end up paying dividends. While YOSPRALA® is unlikely to ever live up to its original billing, its nice to see patients and prescribers responding favorably to the new pricing strategy. We will continue with updates on sales for Zontivity® and YOSPRALA® throughout the year, and are cautiously optimistic this may be the beginning of a turn around for the company. Our valuation remains $6.00, and now may be a good time for those with a high-risk tolerance to consider an investment in Aralez.
### PROJECTED FINANCIALS

**Aralez Pharmaceuticals Inc.**

**Income Statement**

<table>
<thead>
<tr>
<th>Aralez Pharmaceuticals, Inc.</th>
<th>2016 A</th>
<th>Q1 A</th>
<th>Q2 E</th>
<th>Q3 E</th>
<th>Q4 E</th>
<th>2017 E</th>
<th>2018 E</th>
<th>2019 E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vimovo (royalty)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$14.2</td>
<td>$12.0</td>
<td>$11.0</td>
</tr>
<tr>
<td>YOY Growth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-29.9%</td>
<td>-15.3%</td>
<td>-8.3%</td>
</tr>
<tr>
<td><strong>Zontivity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$2.9</td>
<td>$3.5</td>
<td>$8.0</td>
</tr>
<tr>
<td>YOY Growth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Toprol XL</strong></td>
<td>$8.0</td>
<td>$15.0</td>
<td>$11.0</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$44.0</td>
<td>$55.0</td>
<td>$53.0</td>
</tr>
<tr>
<td>YOY Growth</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Product Revenues</strong></td>
<td>$25.4</td>
<td>$6.7</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$26.2</td>
<td>$29.5</td>
<td>$35.0</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>$54.3</td>
<td>$26.0</td>
<td>$21.6</td>
<td>$19.8</td>
<td>$19.9</td>
<td>$87.3</td>
<td>$100.0</td>
<td>$107.0</td>
</tr>
<tr>
<td>YOY Growth</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Cost of Goods Sold</strong></td>
<td>$11.8</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$11.2</td>
<td>$18.0</td>
<td>$20.0</td>
</tr>
<tr>
<td><strong>Gross Income</strong></td>
<td>$42.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$76.1</td>
<td>$82.0</td>
<td>$87.0</td>
</tr>
<tr>
<td><strong>Product Gross Margin</strong></td>
<td>78.3%</td>
<td>89.4%</td>
<td>87.0%</td>
<td>85.9%</td>
<td>85.9%</td>
<td>87.2%</td>
<td>82.0%</td>
<td>81.3%</td>
</tr>
<tr>
<td><strong>SG&amp;A</strong></td>
<td>$107.0</td>
<td>$28.0</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$97.0</td>
<td>$100.0</td>
<td>$105.0</td>
</tr>
<tr>
<td>% SG&amp;A</td>
<td>197.1%</td>
<td>107.8%</td>
<td>106.5%</td>
<td>112.6%</td>
<td>115.6%</td>
<td>111.2%</td>
<td>100.0%</td>
<td>98.2%</td>
</tr>
<tr>
<td><strong>SG&amp;A Stock Based Compensation</strong></td>
<td>$11.6</td>
<td>$2.8</td>
<td>$3.5</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$14.3</td>
<td>$15.0</td>
<td>$15.0</td>
</tr>
<tr>
<td>% SG&amp;A Stock Based Compensation</td>
<td>15.7%</td>
<td>0.4%</td>
<td>2.8%</td>
<td>4.0%</td>
<td>6.5%</td>
<td>3.2%</td>
<td>2.0%</td>
<td>2.8%</td>
</tr>
<tr>
<td><strong>R&amp;D</strong></td>
<td>$8.5</td>
<td>$0.1</td>
<td>$0.6</td>
<td>$0.8</td>
<td>$1.3</td>
<td>$2.8</td>
<td>$3.0</td>
<td>$3.0</td>
</tr>
<tr>
<td>% R&amp;D</td>
<td>15.7%</td>
<td>0.4%</td>
<td>2.8%</td>
<td>4.0%</td>
<td>6.5%</td>
<td>3.2%</td>
<td>2.0%</td>
<td>2.8%</td>
</tr>
<tr>
<td><strong>R&amp;D Stock Based Compensation</strong></td>
<td>$0.3</td>
<td>$0.0</td>
<td>$0.1</td>
<td>$0.1</td>
<td>$0.1</td>
<td>$0.2</td>
<td>$0.2</td>
<td>$0.3</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>($84.9)</td>
<td>($7.7)</td>
<td>($8.4)</td>
<td>($10.9)</td>
<td>($11.3)</td>
<td>($38.2)</td>
<td>($36.2)</td>
<td>($36.3)</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>-156.4%</td>
<td>-29.7%</td>
<td>-30.7%</td>
<td>-34.8%</td>
<td>-36.5%</td>
<td>-43.7%</td>
<td>-36.2%</td>
<td>-33.9%</td>
</tr>
<tr>
<td><strong>Interest, Income Net and Other</strong></td>
<td>($3.5)</td>
<td>($6.2)</td>
<td>($6.9)</td>
<td>($6.9)</td>
<td>($6.9)</td>
<td>($26.9)</td>
<td>($26.9)</td>
<td>($26.9)</td>
</tr>
<tr>
<td>Amortization Expense</td>
<td>($12.6)</td>
<td>($8.5)</td>
<td>($8.5)</td>
<td>($8.5)</td>
<td>($8.5)</td>
<td>($34.0)</td>
<td>($34.0)</td>
<td>($34.0)</td>
</tr>
<tr>
<td>Change in Fair Value of Contingent Consideration</td>
<td>$0.0</td>
<td>($4.4)</td>
<td>($4.0)</td>
<td>($4.0)</td>
<td>($4.0)</td>
<td>($16.4)</td>
<td>($16.0)</td>
<td>($16.0)</td>
</tr>
<tr>
<td><strong>Pre-Tax Income</strong></td>
<td>($103.0)</td>
<td>($26.9)</td>
<td>($27.8)</td>
<td>($30.3)</td>
<td>($30.7)</td>
<td>($115.6)</td>
<td>($97.1)</td>
<td>($97.2)</td>
</tr>
<tr>
<td>Taxes</td>
<td>($0.1)</td>
<td>$0.6</td>
<td>$0.8</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$5.0</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>($103.0)</td>
<td>($27.5)</td>
<td>($28.6)</td>
<td>($31.3)</td>
<td>($31.7)</td>
<td>($118.9)</td>
<td>($100.1)</td>
<td>($102.2)</td>
</tr>
<tr>
<td>YOY Growth</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15.5%</td>
<td>-15.8%</td>
<td>2.2%</td>
</tr>
<tr>
<td><strong>Net Margin</strong></td>
<td>-189.7%</td>
<td>-165.7%</td>
<td>-132.2%</td>
<td>-157.8%</td>
<td>-159.0%</td>
<td>-136.2%</td>
<td>-100.1%</td>
<td>-95.5%</td>
</tr>
<tr>
<td><strong>Reported EPS</strong></td>
<td>($1.67)</td>
<td>($0.42)</td>
<td>($0.43)</td>
<td>($0.46)</td>
<td>($0.46)</td>
<td>($1.76)</td>
<td>($1.41)</td>
<td>($1.40)</td>
</tr>
<tr>
<td>Avg. Weighted Shares Outstanding</td>
<td>61.8</td>
<td>65.5</td>
<td>67.0</td>
<td>68.0</td>
<td>69.0</td>
<td>67.4</td>
<td>71.0</td>
<td>73.0</td>
</tr>
</tbody>
</table>

Source: Zacks Investment Research, Inc.  
David Bautz, PhD
DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research (“ZIR”), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer’s business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is a resident outside of Canada and is not an associated person of any Canadian registered adviser and/or dealer and, therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.